Atrasentan Salt Therapy for IgA Nephropathy Progression Delay
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic approaches for IgA nephropathy provide only supportive care and are associated with adverse reactions, leading to a high risk of end-stage renal disease (ESRD) in 30-40% of patients within 20-30 years, without effectively addressing the underlying immune complex deposition and mesangial cell activation.
Innovation Solution
Administering a pharmaceutically acceptable salt of atrasentan, a selective endothelin A (ETA) receptor antagonist, to inhibit mesangial cell activation and immune complex formation in patients with IgA nephropathy, thereby reducing inflammation and fibrosis, and delaying the progression of kidney disease.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapeutic approaches (ACE inhibitors, ARBs, or immunosuppressive drugs) are administered to treat IgA nephropathy, then supportive care is provided, but adverse reactions occur and the underlying immune complex deposition and mesangial cell activation are not effectively addressed
Solution Approach 1:
The patent extracts and addresses the specific pathogenic mechanism of IgA nephropathy by targeting endothelin-1 and its ETA receptor, separating this specific pathway from the general supportive care approach. This allows selective inhibition of mesangial cell activation and immune complex formation without the broad-spectrum adverse effects of immunosuppressive drugs
Solution Approach 2:
Atrasentan acts as an intermediary substance that blocks the interaction between endothelin-1 and the ETA receptor, preventing the downstream effects of mesangial cell activation and immune complex deposition without directly suppressing the immune system, thereby avoiding immunosuppressive adverse reactions
2Reliability
If maximum tolerable dose of ACE inhibitors or ARBs is administered, then supportive care is provided, but the benefits are largely outweighed by adverse reactions
Solution Approach 1:
The patent changes the therapeutic parameter from general hemodynamic management (ACE inhibitors/ARBs) to specific receptor blockade (ETA receptor antagonist). This parameter change allows achieving therapeutic effect through targeted mechanism inhibition rather than maximum dose supportive care, reducing adverse reactions while maintaining benefit
3Reliability
If immunosuppressive drugs are administered, then immune complex formation may be reduced, but adverse reactions significantly outweigh benefits
Solution Approach 1:
The patent converts the harmful over-suppression of the immune system into a beneficial targeted approach. By specifically blocking the endothelin-1/ETA receptor pathway that drives mesangial cell activation, the treatment achieves immune complex suppression effects without the harmful broad immunosuppression, effectively converting potential harm into benefit
4Ease of operation
If no specific disease-modifying therapy is provided, then current supportive care is maintained, but 30-40% of patients develop end-stage renal disease within 20-30 years
Solution Approach 1:
The patent applies preliminary action by targeting the pathogenic mechanism early in the disease course. By blocking endothelin-1/ETA receptor interaction before extensive irreversible kidney damage occurs, the treatment prevents disease progression to ESRD while maintaining operational simplicity through a single targeted mechanism
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 3A~3B
AI summary
Provided herein are methods of treating IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to a subject in need thereof. Also provided herein are methods of decreasing renal inflammation and/or fibrosis, decreasing the occurrence of hematuria, stabilizing eGFR, decreasing the number of IgA-nephropathy associated disease flares, delaying the onset of ESRD, decreasing proteinuria, and decreasing fatigue in a subject having IgA nephropathy, comprising administering a therapeutically effective amount of atrasentan, or a pharmaceutically acceptable salt thereof, to the subject. In some embodiments, the subject has not been previously diagnosed with one or more of diabetic nephropathy, HIV/AIDS, HIV-related nephropathy, prostate cancer, or acute kidney failure.